STOCK TITAN

Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Rigel Pharmaceuticals, Inc. will report its first quarter 2024 financial results on May 7, 2024, followed by a conference call and webcast discussing financial results and business updates. Rigel Pharmaceuticals is focused on developing therapies for hematologic disorders and cancer.

Rigel Pharmaceuticals, Inc. comunicherà i risultati finanziari del primo trimestre del 2024 il 7 maggio 2024, seguiti da una conferenza telefonica e un webcast per discutere i risultati finanziari e gli aggiornamenti aziendali. Rigel Pharmaceuticals si concentra sullo sviluppo di terapie per disturbi ematologici e cancro.
Rigel Pharmaceuticals, Inc. informará sobre sus resultados financieros del primer trimestre de 2024 el 7 de mayo de 2024, seguido de una conferencia telefónica y una transmisión web para discutir los resultados financieros y actualizaciones empresariales. Rigel Pharmaceuticals está enfocado en el desarrollo de terapias para trastornos hematológicos y cáncer.
Rigel Pharmaceuticals, Inc.는 2024년 5월 7일에 2024년 첫 분기 재무 결과를 발표할 예정이며, 재무 결과 및 비즈니스 업데이트에 대해 논의하는 컨퍼런스 콜과 웹캐스트가 이어질 예정입니다. Rigel Pharmaceuticals는 혈액학적 장애 및 암 치료법 개발에 중점을 두고 있습니다.
Rigel Pharmaceuticals, Inc. rapportera ses résultats financiers pour le premier trimestre de 2024 le 7 mai 2024, suivi d'une conférence téléphonique et d'une webdiffusion pour discuter des résultats financiers et des mises à jour de l'entreprise. Rigel Pharmaceuticals se concentre sur le développement de thérapies pour les troubles hématologiques et le cancer.
Rigel Pharmaceuticals, Inc. wird am 7. Mai 2024 die Finanzergebnisse für das erste Quartal 2024 bekannt geben, gefolgt von einer Telefonkonferenz und einem Webcast, um die Finanzergebnisse und Geschäftsneuigkeiten zu besprechen. Rigel Pharmaceuticals konzentriert sich auf die Entwicklung von Therapien für hämatologische Erkrankungen und Krebs.
Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., April 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2024 financial results after market close on Tuesday, May 7, 2024. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.

Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

Investors & Media Contact  
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com 

Media:
David Rosen
Argot Partners
Phone: 212.600.1902
Email: david.rosen@argotpartners.com 

Rigel Pharmaceuticals Logo (PRNewsfoto/Rigel Pharmaceuticals, Inc.)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2024-financial-results-and-business-update-302130846.html

SOURCE Rigel Pharmaceuticals, Inc.

FAQ

When will Rigel report its first quarter 2024 financial results?

Rigel will report its first quarter 2024 financial results after market close on May 7, 2024.

What does Rigel focus on in terms of therapies?

Rigel is dedicated to discovering and providing novel therapies for patients with hematologic disorders and cancer.

Where is Rigel headquartered?

Rigel Pharmaceuticals is based in South San Francisco, California.

Rigel Pharmaceuticals Inc. (New)

NASDAQ:RIGL

RIGL Rankings

RIGL Latest News

RIGL Stock Data

307.03M
17.23M
2.18%
68.06%
2.63%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO